Where at we at a deal and where are we at a financing? Their recent comments about not doing a deal too cheap as to jeopordise a future deal later on is a bit naive IMO. It's still risk on despite what has been achieved to date. As we know, the biotech sector has not been in favour of late and, as demonstrated by OPT recently, there's a reason investors and lenders are wary. So any deal now would be a bonus and may be structured with a bigger payout post approval. After mid readout, there should be enough good info to up the anti and PAR will have much more hand in the negotiation at that point IMO.
Financing is the priority right now and I don't know why they don't sign off if it's there- It shouldn't be an immediate cost based on what they need to draw down as the trial progresses. Of course if it's via some convertible note or based on issuance of capital in the company it's more complex perhaps. Nobody likes uncertainty so the quicker they announce the better as I feel the more time passes, the less hand they have in the negotiation at this point?
PAR Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)